11
2
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6712 |
Tyrphostin AG 879
AG 879 |
Apoptosis; EGFR; Trk receptor; HER; PDGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tyrphostin AG 879 (AG 879) 是一种抑制TrKA 磷酸化的酪氨酸激酶抑制剂,IC50为 10 μM。它还是一种选择性ErbB2酪氨酸激酶抑制剂,IC50为 1 μM,具有抗癌活性。 | |||
T9003 |
CVT-11127
N-[2-[6-[[(3,4-二氯苯基)甲基]氨基]-2-(4-甲氧基苯基)-3-氧代-3,4-二氢吡啶并[2,3-B]吡嗪-4-基]乙基]乙酰胺 |
Dehydrogenase | Metabolism |
CVT-11127 是 SCD 抑制剂。它将细胞周期阻滞在 G1/S 期,诱导细胞凋亡。它可用于肺癌的研究。 | |||
T64387 |
2-Nitrobenzoic acid
o-Nitrobenzoic acid |
Others | Others |
2-Nitrobenzoic acid (o-Nitrobenzoic acid) 是一种抗增殖化合物,对表达 T 型钙通道α1H 或其剪接变体δ25的 jurkat 细胞系显示出8.3μM 的 IC50。 | |||
T27524 |
H8-A5
H8 A5 |
||
H8-A5, a HDAC8 inhibitor, shows antiproliferation activity in MDA-MB-231 cancer cells. | |||
T26238 |
Sumarotene
Ro14-9706,Ro-14-9706,Ro 14-9706 |
||
Sumarotene, a third-generation retinoid, is used as a topical dermatologic agent for the repair of antikeratinization, photodamage, and antiproliferation. | |||
T61429 | HDAC-IN-33 | ||
HDAC-IN-33 is a highly potent HDAC inhibitor, effectively inhibiting HDAC1, HDAC2, and HDAC6 with IC50 values of 24, 46, and 47 nM, respectively. This compound demonstrates significant antiproliferation activity against tumor cells and exhibits remarkable in vivo antitumor efficacy. Additionally, HDAC-IN-33 initiates the activation of antitumor immunity [1]. | |||
T70628 |
Cmpd-A
|
||
Cmpd-A is a time-dependent CENP-E inhibitor with potent antitumor activity. Cmpd-A inhibits the ATPase activity of the CENP-E motor domain, acting as a time-dependent inhibitor with an ATP-competitive-like behavior. Cmpd-A causes chromosome misalignment on the metaphase plate, leading to prolonged mitotic arrest. Treatment with Cmpd-A induces antiproliferation in multiple cancer cell lines. | |||
T71267 |
GNF-8625
|
||
GNE-8525 is a potent and selective pan-TRK inhibitor. GNE-8525 demonstrated potent antiproliferation activity with IC50 = 0.003 μM. In a tumor xenograft model derived from the KM12 cell line, GNE-8525 demonstrated in vivo antitumor efficacy when administered at ascending doses twice daily (bid) for 14 days in rats. Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer type... | |||
T61978 |
ACC1/2-IN-2
|
||
ACC1/2-IN-2 (compound PF-3) 是有效的 ACC1/2抑制剂,IC50分别为 22 和 48 nM。 ACC1/2-IN-2 显示出抗增殖活性,可用于癌症相关研究。 | |||
T63351 | MS8511 | ||
MS8511 是一种选择性的G9a/GLP 共价的不可逆抑制剂,可靶向底物结合位点的半胱氨酸残基,IC50值为 100 nM ( G9a) 和 140 nM (GLP),Kd 值44 nM (G9a) 和 46 nM (GLP)。 MS8511 可降低细胞内 H3K9me2 水平并提高抗增殖活性。MS8511 可用于研究多种癌症 (包括脑癌、乳腺癌、卵巢癌、肺癌、膀胱癌、黑色素瘤、结肠直肠癌) 和其他疾病,如阿尔茨海默病 (AD)、镰状细胞病、Prader-Willi 综合征 (PWS). | |||
T36628 |
PROTAC BRD4 Degrader-8
PROTAC BRD4 Degrader-8 |
||
PROTAC BRD4 Degrader-8 is a potent BRD4 inhibitor, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells[1]. PROTAC BRD4 Degrader-8 (compound 8; 6 days) inhibits the proliferation of PC3 prostate cancer cells, with an IC50 of 28 nM[1].PROTAC BRD4 Degrader-8 (4 h) suppresses MYC gene transcript in MV4-11 AML cells, with an IC50 of 11 nM[1].PROTAC BRD4 Degrader-8 (4 h) potently degra... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2P2806 |
Hederacolchiside A1
黑海常春藤苷A1,革叶常春藤皂苷 A1,Raddeanoside R13 |
Apoptosis; ERK; MEK; Akt; PI3K; Parasite; mTOR | Apoptosis; Cytoskeletal Signaling; MAPK; Microbiology/Virology; PI3K/Akt/mTOR signaling |
Hederacolchiside A1 (Raddeanoside R13) 是从白头翁中分离的一种有抗利什曼原虫和抗肿瘤增殖活性的天然产物。 | |||
T36715 |
Tetrac
Tetraiodothyroacetic acid,3,3',5,5'-Tetraiodothyroacetic acid |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tetrac (Tetraiodothyroacetic acid)是L-甲状腺素(T4)的衍生物,是一种甲状腺整合素受体拮抗剂。Tetrac通过阻断EGFR介导的结直肠癌细胞信号传导来诱导抗增殖。Tetrac 可阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3)在细胞表面甲状腺素整合素 αvβ3 受体上的作用。Tetra 具有抗血管生成、抗肿瘤活性和促凋亡活性。 |